叔丁基(环丙基甲基)氨基甲酸酯 | 897932-58-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 叔丁基(环丙基甲基)氨基甲酸酯
• 英文名称: tert-butyl (cyclopropylmethyl)carbamate
• 英文别名: tert-butyl N-(cyclopropylmethyl)carbamate
• CAS: 897932-58-0
• 化学式: C₉H₁₇NO₂
• mdl: MFCD11976857
• 分子量: 171.239
• InChiKey: ZPOIEEISPMGDRW-UHFFFAOYSA-N

物化性质

• 沸点：
  248.6±9.0 °C(Predicted)
• 密度：
  1.012±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  叔丁基(环丙基甲基)氨基甲酸酯 在 正丁基锂 、 四甲基乙二胺 、 sodium hydride 作用下， 以 四氢呋喃 、 正己烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 17.5h， 生成 (Z)-tert-butyl (cyclopropylmethyl)(3-(p-tolyl)prop-1-en-1-yl)carbamate
  参考文献：
  名称：

  Palladium-Catalyzed γ-Selective Arylation of Zincated Boc-Allylamines

  摘要：

  The regio- and diastereoselective arylation of Boc-protected allylamines was performed via a one-pot lithiation/transmetalation to zinc/cross-coupling sequence, through an appropriate choice of a phosphine ligand. A variety of γ-arylated products were obtained in moderate to good yield, and the products could be directly transformed into valuable γ-arylamines and β-aryl aldehydes.

  DOI：

  10.1021/ol5018257
• 作为产物：
  描述：

  碳酸二叔丁酯 、 环丙基甲胺 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以90%的产率得到叔丁基(环丙基甲基)氨基甲酸酯
  参考文献：
  名称：

  Palladium-Catalyzed γ-Selective Arylation of Zincated Boc-Allylamines

  摘要：

  The regio- and diastereoselective arylation of Boc-protected allylamines was performed via a one-pot lithiation/transmetalation to zinc/cross-coupling sequence, through an appropriate choice of a phosphine ligand. A variety of γ-arylated products were obtained in moderate to good yield, and the products could be directly transformed into valuable γ-arylamines and β-aryl aldehydes.

  DOI：

  10.1021/ol5018257

文献信息

• [EN] NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS 2-PIPERIDIN-1-YL-ACETAMIDE UTILISABLES EN TANT QU'INHIBITEURS DE TANKYRASE
  申请人：NOVARTIS AG

  公开号：WO2013012723A1

  公开（公告）日：2013-01-24

  The present invention provides for compounds of formula (I), wherein R1-R5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.

  本发明提供了式(I)的化合物，其中R1-R5和L在此处定义。本发明还提供了包含式(I)化合物的药物组合物和组合物，以及将这些化合物用作坦基酶抑制剂以及用于治疗Wnt信号和坦基酶1和2信号相关疾病的用途，包括但不限于癌症。
• Synthesis of 2-Aminoindolizines by 1,3-Dipolar Cycloaddition of Pyridinium Ylides with Electron-Deficient Ynamides
  作者：Julien Brioche、Christophe Meyer、Janine Cossy

  DOI：10.1021/acs.orglett.5b01205

  日期：2015.6.5

  possessing an ynoate or an ynone moiety, have been successfully involved for the first time in a 1,3-dipolar cycloaddition with stabilized pyridinium ylides. These reactions afford an efficient and general access toward a variety of substituted 2-aminoindolizines which can serve as useful precursors for the synthesis of other more complex nitrogen heterocycles.

  具有炔酸或炔酮部分的电子不足的酰胺，已首次成功地与稳定的吡啶鎓碘化物进行1,3-偶极环加成反应。这些反应为各种取代的2-氨基吲哚嗪提供了有效且普遍的途径，这些取代的2-氨基吲哚嗪可以用作合成其他更复杂的氮杂环的有用前体。
• [EN] BIARYL DERIVATIVES AS GPR120 AGONISTS<br/>[FR] DÉRIVÉS DE BIARYLE EN TANT QU'AGONISTES DE GPR120
  申请人：LG LIFE SCIENCES LTD

  公开号：WO2014209034A1

  公开（公告）日：2014-12-31

  The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.

  本发明涉及公式1的联苯衍生物，一种制备该联苯衍生物的方法，包含该联苯衍生物的药物组合物以及其用途。根据本发明的公式1的联苯衍生物促进胃肠道中GLP-1的形成，并由于巨噬细胞、脂肪细胞等中的抗炎作用改善肝脏或肌肉中的胰岛素抵抗，因此可有效用于预防或治疗糖尿病、糖尿病并发症、肥胖、非酒精性脂肪肝、脂肪性肝炎、骨质疏松症或炎症。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015180613A1

  公开（公告）日：2015-12-03

  The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

  本发明涉及新型视黄醇相关孤儿受体γ（RORγ）调节剂及其在治疗由RORγ介导的疾病中的应用。
• FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF
  申请人：Song Ho Young

  公开号：US20110112083A1

  公开（公告）日：2011-05-12

  The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.

  本发明涉及具有环氨基羟肟或环氨基脒基团的新型噁唑烷酮衍生物，其药学上可接受的盐，制备方法以及包含它们的药物组合物。具有环氨基羟肟或环氨基脒基团的噁唑烷酮衍生物或其药学上可接受的盐可有效用于作为抗凝剂治疗血栓栓塞和肿瘤，基于对因子Xa的抑制。